Shandong Boan Biotechnology Co., Ltd. (BOAN BIOTECH) has filed its Monthly Return for the period ended 31 July 2026 with Hong Kong Exchanges and Clearing, confirming an unchanged capital structure and continued compliance with public-float requirements.

Share Capital and Issued Shares • Registered share capital held steady at 622.33 million ordinary H shares, each with a par value of RMB 1, translating to total registered capital of RMB 622.33 million. • Issued H shares totalled 622.33 million, identical to the previous month. No new shares were issued, repurchased, or cancelled, and the company held zero treasury shares.

Public-Float Status • BOAN BIOTECH reconfirmed that its public float satisfies the waiver granted by the Stock Exchange, which sets the minimum at 18.14 % of issued share capital. As at 31 July 2026, the public float met this threshold.

Equity-Linked Instruments and Other Movements • The company reported no share options, warrants, convertible securities, or other equity-linked arrangements during the month. • No other movements in issued or treasury shares were recorded.

Regulatory Confirmation Director Jiang Hua certified that all prior securities transactions comply with the Listing Rules, relevant laws, and regulatory filings.

The July 2026 return highlights a stable equity base and adherence to listing obligations, with no dilution or structural changes affecting shareholders during the month.